Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
1.
Biomarkers ; 21(7): 645-52, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27120970

ABSTRACT

CONTEXT: Early diagnosis of complications after severe trauma by specific biomarkers remains difficult. OBJECTIVE: Identify potential new biomarkers for early diagnosis of post-traumatic complications. MATERIAL AND METHODS: Mice underwent pressure-controlled hemorrhage or sham procedure. Four hours later, genome-wide expression of isolated Kupffer cells was compared with controls using Affymetrix-Genechip-Expression-Analysis and real-time-PCR. RESULTS: Expression analysis and real-time-PCR revealed a significant increase of gene expression of Cxcl10, Il4ra, Csf2rb2, Lcn2, and Gbp5. CONCLUSION: Cxcl10, Il4ra, Csf2rb2, Lcn2, and Gbp5 might represent new biomarkers for early diagnosis of post-traumatic complications, if they are linked to the development of post-traumatic complications.


Subject(s)
Biomarkers , Hemorrhage/metabolism , Kupffer Cells/metabolism , Wounds and Injuries/complications , Animals , Chemokine CXCL10/analysis , GTP-Binding Proteins/analysis , Genome-Wide Association Study , Lipocalin-2/analysis , Liver/metabolism , Lung/metabolism , Mice , Receptors, Cell Surface/analysis , Receptors, Interleukin-3/analysis , Up-Regulation
2.
Neoplasma ; 56(2): 89-95, 2009.
Article in English | MEDLINE | ID: mdl-19239320

ABSTRACT

UNLABELLED: BioBran, enzymatically modified arabinoxylan from rice bran was tested for its possible effects on in vitro maturation of human dendritic cells (DC). Immature DC (iDC) derived from plastic-adhered, IL-4 and GM-CSF treated peripheral monocytes (Mo) were further cultured with cytokine maturation mix 1 (CMM1; TNF-alpha, IL-1beta and IL-6) or CMM2 (LPS and IFN-gamma) to induce their maturation into mature DC (matDC1 or matDC2, respectively). Different concentrations of BioBran (10, 100, 400 and 1000 microg/ml) were applied in the presence or absence of relevant CMM to assess the effects of BioBran on DC maturation processes. BioBran induced maturation of iDC, as these cells cultured with IL-4/GM-CSF/BioBran down-regulated CD14 and CD1a antigens on cell surface and significantly increased expression of maturation marker CD83. The increase of surface density of costimulatory molecules CD80 and CD86 on iDC in the presence of BioBran was also observed. In addition, BioBran induced functional maturation of iDC, confirmed by decreased endocytic activity of iDC. Further emore, BioBran enhanced maturation potential of cytokine mixes, as both matDC1 and matDC2 exposed to BioBran completely lost CD14 and upregulated CD83, CD80 and CD86 antigens, in comparison to DC matured with the relevant CMM alone. BioBran also increased CD123 antigen expression on all DC subsets. Interestingly, matDC2 matured in the presence of BioBran (400microg/ml) expressed higher levels of CD123 and lower levels of CD11c cell surface antigens, the phenotype represented by CD11cdim CD123bright plasmacytoid DC population. These data demonstrate that BioBran is a potent enhancer of DC maturation and suggest that BioBran might be a useful agent to create the environment that favours DC maturation. KEYWORDS: Dendritic cell, maturation, BioBran, buffy coat.


Subject(s)
Dendritic Cells/drug effects , Monocytes/cytology , Xylans/pharmacology , B7-1 Antigen/analysis , B7-2 Antigen/analysis , Cell Differentiation/drug effects , Dendritic Cells/immunology , Dendritic Cells/physiology , Endocytosis/drug effects , Humans , Interleukin-3 Receptor alpha Subunit/analysis , Receptors, Interleukin-3/analysis
3.
Leukemia ; 22(7): 1395-401, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18509353

ABSTRACT

Relapse in acute myeloid leukaemia (AML) is mediated by survival of leukaemic stem cells following remission-induction chemotherapy. It would therefore be useful to identify therapeutic agents that target leukaemic stem cells. We devised a flow cytometric chemosensitivity assay allowing 48 h culture of leukaemic blasts in a defined microenvironment followed by enumeration of viable CD34+CD38-CD123+ leukaemic stem and progenitor cells (LSPC). The assay was used to investigate the LSPC response to cytosine arabinoside (Ara-C) and to the FLT3 inhibitor AG1296. There was a 3.6-fold increase in Ara-C-treated LSPC survival under defined 'niche-like' conditions compared to culture without microenvironmental support. Nine AML samples with internal tandem duplications of FLT3 (FLT3/ITDs) were treated with AG1296. Three samples were very sensitive (>50% kill) and 4 were moderately sensitive (10-50% kill) in bulk suspension culture without microenvironmental support. However, under defined 'niche-like' conditions, the survival of LSPC was enhanced rather than inhibited by AG1296 treatment. We conclude that an interaction between LSPC and a defined in vitro microenvironment models a chemoresistant niche. Our data point to a need to investigate more novel chemotherapeutic agents under these stringent conditions to identify agents that may be suitable to target minimal residual disease in AML.


Subject(s)
Leukemia, Myeloid, Acute/drug therapy , Neoplastic Stem Cells/drug effects , Tyrphostins/pharmacology , fms-Like Tyrosine Kinase 3/antagonists & inhibitors , ADP-ribosyl Cyclase 1/analysis , Antigens, CD34/analysis , Cell Line, Tumor , Cell Survival/drug effects , Cytarabine/pharmacology , Drug Resistance, Neoplasm , Humans , Interleukin-3 Receptor alpha Subunit/analysis , Leukemia, Myeloid, Acute/pathology , Membrane Glycoproteins/analysis , Phenotype , Receptors, Interleukin-3/analysis , fms-Like Tyrosine Kinase 3/genetics
4.
Transplant Proc ; 39(10): 3101-4, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18089331

ABSTRACT

Dendritic cells (DCs) play a key role in transplantation tolerance and immune reactions to transplants. In order to ascertain whether DC levels are predictive for rejection, we examined the levels and expression patterns of DCs of renal transplant patients following immunosuppressive and/or surgical interventions. Myeloid (HLA-DR+/CD11c+) and plasmacytoid (HLA-DR+/CD123+) DCs were characterized by flow cytometry over 28 days. We demonstrated that myeloid DCs and plasmacytoid DCs in peripheral blood were discernable and dramatically decreased following renal transplantation and immunosuppression. Furthermore, the expression of CD62L was significantly up-regulated (P=.032), while CD86 was significantly down-regulated (P=.008) on myeloid but not plasmacytoid DCs. Although DC levels alone were not predictive for the occurrence of a rejection episode, in combination with other factors they may be indicative of rejection, thereby sparing the patient a biopsy.


Subject(s)
Dendritic Cells/classification , Kidney Transplantation/immunology , Antigens, CD/analysis , CD11c Antigen/analysis , Dendritic Cells/immunology , Graft Rejection/immunology , HLA-DR Antigens/analysis , Humans , Interleukin-3 Receptor alpha Subunit/analysis , Predictive Value of Tests , Receptors, Interleukin-3/analysis , Reference Values
5.
Hum Immunol ; 68(5): 324-33, 2007 May.
Article in English | MEDLINE | ID: mdl-17462499

ABSTRACT

Two major populations of dendritic cells (DCs), myeloid and plasmacytoid, can be isolated from human peripheral blood, and are distinguished by differential expression of the cell surface markers CD11c and CD123. These two populations of DCs also are different in their expression of Toll-like receptor (TLRs), which are involved in their activation. To investigate the early events during activation of peripheral DCs, the cells were stimulated in vitro with ligands for TLR-4 (as in lipopolysaccharides [LPS]) or TLR-9 (CpG-containing oligonucleotide [CpG]). The earliest change in protein expression detected after stimulating peripheral DCs with lipopolysaccharide (LPS) or CpG was increased production of the chemokine interleukin (IL)-8. Enhanced production of IL-8 occurred already within 2 hours of stimulation in both myeloid dendritic cells (M-DCs) and plasmacytoid dendritic cells (P-DCs), and preceded expression of the well established activation marker CD40. Although both populations of DCs secreted IL-8 upon activation, the levels of IL-8 produced was several times higher within the M-DCs compared with the P-DCs population. Before activation, both subsets of DCs expressed the IL-8 receptor type B (CD128b); but after stimulation the IL-8 receptor was down-regulated in both populations of DCs. Increased expression of MHC class II molecules is generally regarded as an early activation marker of DCs. However, only the P-DCs showed a significant up-regulation of MHC class II after stimulation. The M-DC population up-regulated MHC class II without any prior activation; thus care should be taken using increased expression of MHC class II molecules as an early activation marker of peripheral M-DCs after activation in vitro. In conclusion, we propose that during activation of human DCs the production of IL-8 and loss of CD128b are the earliest signs of activation preceding both MHC class II, CD40, CD80, and CD86 expression.


Subject(s)
Antigens, CD/metabolism , Dendritic Cells/metabolism , Interleukin-8/metabolism , Receptors, Interleukin-8B/metabolism , Antigens, CD/analysis , B7-1 Antigen/metabolism , B7-2 Antigen/metabolism , CD11c Antigen/analysis , CD40 Antigens/metabolism , CpG Islands/genetics , Dendritic Cells/cytology , Dendritic Cells/drug effects , HLA-D Antigens/metabolism , Histocompatibility Antigens Class I/metabolism , Humans , Interferon-alpha/metabolism , Interleukin-3 Receptor alpha Subunit/analysis , Interleukins/metabolism , Kinetics , Lipopolysaccharides/pharmacology , Oligodeoxyribonucleotides/genetics , Oligodeoxyribonucleotides/pharmacology , Receptors, Interleukin-3/analysis , Tumor Necrosis Factor-alpha/metabolism
6.
Blood ; 108(10): 3530-7, 2006 Nov 15.
Article in English | MEDLINE | ID: mdl-16882709

ABSTRACT

The interleukin-3 receptor (IL-3R) subunits are overexpressed on acute myeloid leukemia (AML) blasts compared with normal hematopoietic cells and are thus potential targets for novel therapeutic agents. Both fluorescence-activated cell sorter (FACS) analysis and quantitative real-time reverse transcription-polymerase chain reaction (QRT-PCR) were used to quantify expression of the IL-3Ralpha and beta(c) subunits on AML cells. QRT-PCR for both subunits was most predictive of killing of AML colony-forming cells (AML-CFCs) by diphtheria toxin-IL-3 fusion protein (DT(388)IL3). Among 19 patient samples, the relative level of the IL-3Ralpha was higher than the IL-3Rbeta(c) and highest in CD34(+)CD38(-)CD71(-) cells, enriched for candidate leukemia stem cells, compared with cell fractions depleted of such progenitors. Overall, the amount of IL-3Rbeta(c) subunit did not vary among sorted subpopulations. However, expression of both subunits varied by more than 10-fold among different AML samples for all subpopulations studied. The level of IL-3Rbeta(c) expression versus glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (set at 1000) ranged from 0.14 to 13.56 in CD34(+)CD38(-)CD71(-) cells from different samples; this value was correlated (r = .76, P = .05) with the ability of DT(388)IL3 to kill AML progenitors that engraft in beta(2)-microglobin-deficient nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice (n = 7). Thus, quantification of IL-3R subunit expression on AML blasts predicts the effectiveness IL-3R-targeted therapy in killing primitive leukemic progenitors.


Subject(s)
Antineoplastic Agents/administration & dosage , Diphtheria Toxin/therapeutic use , Drug Delivery Systems , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/pathology , Predictive Value of Tests , Receptors, Interleukin-3/analysis , Acute Disease , Adolescent , Adult , Aged , Animals , Blast Crisis/pathology , Cytokine Receptor Common beta Subunit/analysis , Female , Humans , Immunophenotyping , Interleukin-3 Receptor alpha Subunit/analysis , Leukemia, Myeloid/diagnosis , Male , Mice , Mice, SCID , Middle Aged , Neoplasm Proteins/analysis , Neoplasms, Experimental , Neoplastic Stem Cells/transplantation , Prognosis , Recombinant Fusion Proteins/therapeutic use
7.
Int Endod J ; 39(8): 626-36, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16872457

ABSTRACT

AIM: To analyse phenotypic characteristics of antigen-presenting cells (APC), isolated from human periapical lesions by flow cytometry and immunocytochemistry. METHODOLOGY: Sixteen periapical lesions were digested for 15 min with 0.05% collagenase. Mononuclear cells, separated from other inflammatory cells by density centrifugation, were processed for flow cytometry and/or immunocytochemistry. Single and double immunostainings were performed using monoclonal antibodies specific for human CD45, CD3, CD19, CD14, HLA-DR, CD1a, CD83 and CD123. RESULTS: Antigen-presenting cells (HLA-DR(+) cells) represented 32.9 +/- 17.8% of total mononuclear cells. Amongst them, B cells (HLA-DR(+) CD19(+)) were the predominant APC population, followed by activated macrophages (HLA-DR(+) CD14(+)), dendritic cells (DC) (HLA-DR(+) CD14(-) CD19(-) CD3(-)) and activated T cells (HLA-DR(+) CD3(+)). Based on the predominance of T cells (CD3(+)) or B cells and plasma cells (CD19(+) and CD19(lo), respectively) amongst mononuclear cell infiltrates, lesions were divided into T- and B-types. The percentage of DC in T-type lesions (27.1 +/- 6.8% of total HLA-DR(+) cells) was higher, compared with B-type lesions (10.3 +/- 5.2%) (P < 0.01). Within the DC population, the percentages of CD1a (Langerhans cell type) and CD123 (probably plasmacytoid DC type) did not differ significantly between the groups (P > 0.05). However, the percentage of mature DC (CD83(+)) was significantly higher in T-type periapical lesions (P < 0.05). CONCLUSIONS: Flow cytometry and immunocytochemistry are suitable methods for phenotypic analysis of APC after their isolation from human periapical lesions. APC, that were phenotypically heterogeneous, constituted a significant component of infiltrating cells. Lesions with the predominance of T cells were characterized by a higher proportion of mature DC (HLA-DR(+)CD83(+) cells) than lesions with predominance of B cells/plasma cells.


Subject(s)
Antigen-Presenting Cells/pathology , Periapical Periodontitis/pathology , Adolescent , Adult , Antigen-Presenting Cells/classification , Antigens, CD/analysis , Antigens, CD1/analysis , Antigens, CD19/analysis , B-Lymphocytes/pathology , CD3 Complex/analysis , Dendritic Cells/pathology , Flow Cytometry , HLA-DR Antigens/analysis , Humans , Immunoglobulins/analysis , Immunohistochemistry , Immunophenotyping , Interleukin-3 Receptor alpha Subunit , Leukocyte Common Antigens/analysis , Lipopolysaccharide Receptors/analysis , Lymphocyte Activation , Macrophages/pathology , Membrane Glycoproteins/analysis , Middle Aged , Periapical Periodontitis/immunology , Plasma Cells/pathology , Receptors, Interleukin-3/analysis , T-Lymphocytes/pathology , CD83 Antigen
8.
J Dtsch Dermatol Ges ; 4(6): 492-5, 2006 Jun.
Article in German | MEDLINE | ID: mdl-16734840

ABSTRACT

Primary cutaneous lymphomas are characterized by an expansion of hematopoietic cells in the special microenvironment of the skin. They represent a special challenge both for researches and for clinicians who treat patients with these disorders. New research data concerning the biology of lymphocytes and the cutaneous microenvironment have increased our knowledge of these diseases in the last decades. The new WHO/EORTC classification definitely will facilitate a more detailed investigation of the various subtypes.


Subject(s)
Lymphoma, B-Cell/pathology , Lymphoma, T-Cell, Cutaneous/pathology , Skin Neoplasms/pathology , Biomedical Research , CD4 Antigens/analysis , CD56 Antigen/analysis , Cell Transformation, Neoplastic/pathology , Dendritic Cells/pathology , Hematopoietic System/pathology , Humans , Interleukin-3 Receptor alpha Subunit , Lectins, C-Type/analysis , Lymphoma, B-Cell/classification , Lymphoma, T-Cell, Cutaneous/classification , Membrane Glycoproteins/analysis , Plasma Cells/pathology , Receptors, Immunologic/analysis , Receptors, Interleukin-3/analysis , Skin/pathology , Skin Neoplasms/classification
9.
Stem Cells Dev ; 15(2): 269-77, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16646673

ABSTRACT

Dendritic cells (DCs) are the most efficient antigen-presenting cells and play a role in immune reconstitution after autologous transplantation. Recent reports suggest that mobilization with granulocyte colony-stimulating factor (G-CSF) containing regimens polarizes DCs into pDC2, which could potentially result with increased Th2 response and decreased graft-versus-host disease (GVHD) in allogeneic transplantation and with decreased cytotoxic Th1 response and graft versus tumor effect, which in autologous transplantation could translate into increased relapse rate. Previously, we have shown that non-Hodgkin's lymphoma (NHL) patients receiving cyclophosphamide (CTX) plus granulocyte- macrophage (GM)-CSF, G-CSF or GM-CSF followed by G-CSF for stem cell collection, mobilize up to five-fold more mature CD80(+) DCs compared to CTX plus G-CSF mobilized patients. Here, we analyzed samples from the same study for the number of pDC1 and pDC2 subsets in blood and apheresis products obtained from these patients. Samples from 29 patients were collected. Patients mobilized with CTX plus G-CSF collected a mean of 1.2 +/- 0.4 x 10(6) pDC1/kg per day and 2.2 +/- 1 x 10(6) pDC2/kg per day, whereas patients mobilized with CTX plus GM-CSF collected a mean of 1.1 +/- 0.5 x 10(6) pDC1 and 1.5 +/- 0.9 x 10(6) pDC2/kg per day. Patients mobilized with CTX plus GM-CSF followed by G-CSF collected 2.5 +/- 1.1 x 10(6) pDC1 and 2 +/- 0.5 x 106 pDC2/kg per day, with significantly higher levels of pDC1 +/- pDC2 cells. No significant difference was observed in pDC1/pDC2 ratio between the three mobilization arms. Patients mobilized with the GM-CSFcontaining regimen had a higher probability for survival compared to patients receiving G-CSF alone (median of 55 months vs. 15 months; p = 0.02). These results support the hypothesis that higher levels of DCs in the graft might be associated with prolonged survival of autotransplanted NHL patients. Further similar studies are merited in a larger population of NHL patients.


Subject(s)
Cyclophosphamide/pharmacology , Dendritic Cells/cytology , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cell Mobilization/methods , Lymphoma, Non-Hodgkin/therapy , Adult , Aged , Antigens, CD34/analysis , Blood Component Removal , Bone Marrow/drug effects , CD11c Antigen/analysis , Dendritic Cells/chemistry , Female , Granulocyte Colony-Stimulating Factor/administration & dosage , Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage , HLA-DR Antigens/analysis , Hematopoietic Stem Cell Transplantation/methods , Humans , Interleukin-3 Receptor alpha Subunit , Leukocytes/chemistry , Leukocytes/cytology , Male , Middle Aged , Receptors, Interleukin-3/analysis , Survival Analysis , Transplantation, Autologous
10.
Pediatr Res ; 60(1): 34-7, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16690948

ABSTRACT

Neonates are more susceptible than adults to viral and bacterial diseases. We hypothesized that plasmacytoid dendritic cells, the cells that provide large amounts of IFN-alpha in response to Toll-like receptor 9 (TLR9) agonists, are defective in neonates. To assess the intrinsic functionality of plasmacytoid dendritic cells from neonates we compared IFN-alpha production by plasmacytoid dendritic cells derived from neonates versus adults in both whole blood and in purified plasmacytoid dendritic cells. TLR9-stimulation of whole blood from adults and neonates resulted in comparable amounts of IFN-alpha production. However, we observed small but significant differences in IFN-alpha production from purified CD123+ plasmacytoid dendritic cells from neonates after stimulation with the TLR9 ligand CpG-DNA. Furthermore, we assessed surface expression of co-stimulatory molecules on plasmacytoid dendritic cells after stimulation. While purified CD123+ plasmacytoid dendritic cells from adults up-regulated co-stimulatory molecules CD80 and CD86 with IL-3 alone those from neonates required the addition of CpG-DNA to reach adult levels. Therefore, the intrinsic deficiencies of neonatal plasmacytoid dendritic cells can be mitigated by TLR9 agonists. These results are consistent with the observation that vaccines that effect strong adjuvant activity on dendritic cells can induce protective responses in neonates.


Subject(s)
Dendritic Cells/drug effects , Dendritic Cells/metabolism , Interferon-alpha/metabolism , Oligodeoxyribonucleotides/pharmacology , Toll-Like Receptor 9/agonists , Adult , Aging/immunology , Aging/physiology , B7-1 Antigen/analysis , B7-1 Antigen/genetics , B7-2 Antigen/analysis , B7-2 Antigen/genetics , Base Sequence , Cell Differentiation/immunology , Cell Differentiation/physiology , Cell Separation , Cells, Cultured , DNA/genetics , Dendritic Cells/immunology , Humans , Infant, Newborn , Interleukin-3/physiology , Interleukin-3 Receptor alpha Subunit , Oligodeoxyribonucleotides/genetics , Receptors, Interleukin-3/analysis , Toll-Like Receptor 9/physiology , Up-Regulation/drug effects , Up-Regulation/physiology
11.
Hum Pathol ; 36(9): 1020-4, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16153467

ABSTRACT

CD4+CD56+ hematodermic neoplasms (HNs) with initial presentation in the skin are characterized by highly aggressive behavior and poor prognosis. Recent studies indicate that malignant cells, which are devoid of common T-, B-, NK-, and myeloid lineage markers, may be of plasmacytoid dendritic cell (pDC) origin. We undertook a study to assess the expression of several pDC-associated molecules on a series of 5 CD4+CD56+ HN cases. CD123 was expressed in all 5 cases, with some heterogeneity in individual cases. All but one case revealed fine membranous BDCA-2 staining of the dermal infiltrate. pDC-like phenotype of the malignant infiltrating cells was confirmed by costaining of BDCA-2+ cells with CD123 and CD4. MxA protein, representing the surrogate marker for lesional type I interferon activity, was expressed in 4 of 5 evaluated cases. Our findings further substantiate the putative pDC origin of CD4+CD56+ HNs.


Subject(s)
CD4 Antigens/analysis , CD56 Antigen/analysis , Dendritic Cells/pathology , Lymphoma/pathology , Skin Neoplasms/pathology , Adult , Aged , Biomarkers, Tumor/analysis , Cell Lineage , Dendritic Cells/immunology , Female , GTP-Binding Proteins/analysis , Humans , Immunophenotyping , Interleukin-3 Receptor alpha Subunit , Lectins, C-Type/analysis , Lymphoma/immunology , Male , Membrane Glycoproteins/analysis , Middle Aged , Myxovirus Resistance Proteins , Receptors, Immunologic/analysis , Receptors, Interleukin-3/analysis , Skin Neoplasms/immunology
12.
Cancer ; 104(5): 1022-31, 2005 Sep 01.
Article in English | MEDLINE | ID: mdl-15999368

ABSTRACT

BACKGROUND: Blastic natural killer (NK) cell lymphoma/leukemia (BNKL) is an immature CD56-positive neoplasm, which was recognized recently and characterized by systemic proliferation of tumor cells including skin, lymph node, and bone marrow. METHODS: The current study analyzed 47 patients with BNKL (27 had leukemias and 20 had lymphomas). Patient data were collected for the survey of the NK-Cell Tumor Study Group. RESULTS: There were 33 males and 14 females, with a median age of 53 years (range, 3 months to 89 years). There were few clinicopathologic differences between the leukemia and lymphoma types. Cutaneous involvement was noted at diagnosis in 28 patients, who presented a tendency for older age of onset (median: 56 vs. 46 years, P = 0.11) than patients with noncutaneous BNKL. Cutaneous BNKL showed less frequent mediastinal involvement (4% vs. 53%, P = 0.0002) and less severe thrombocytopenia (P =0 .03). Phenotypic characteristics were also different, with cutaneous BNKL favoring CD4 and HLA-DR expression, and noncutaneous BNKL favoring CD16 and CD34 expression. Both groups responded well to chemotherapy for lymphoid malignancies, but disease recurrence was frequent. The prognosis of patients with noncutaneous BNKL was significantly poorer than that of patients with cutaneous BNKL (median survival: 15 vs. 25 months, P = 0.02). Multivariate analysis confirmed that cutaneous involvement was a significant and independent prognostic factor for BNKL, as were age of onset and leukocyte count. CONCLUSIONS: These findings suggested that BNKL is a heterogeneous disease and contains at least two subtypes. Although further investigations are needed to settle a marker for distinction, the presence of cutaneous involvement is a useful prognostic factor.


Subject(s)
CD56 Antigen/analysis , Killer Cells, Natural/pathology , Leukemia, Lymphoid/mortality , Lymphoma, T-Cell/mortality , Adolescent , Adult , Aged , Aged, 80 and over , DNA Nucleotidylexotransferase/analysis , Female , Gene Rearrangement, T-Lymphocyte , Humans , Immunophenotyping , Interleukin-3 Receptor alpha Subunit , Karyotyping , Leukemia, Lymphoid/immunology , Leukemia, Lymphoid/therapy , Lymphoma, T-Cell/immunology , Lymphoma, T-Cell/therapy , Male , Middle Aged , Prognosis , Receptors, Interleukin-3/analysis , Skin Neoplasms/immunology , Skin Neoplasms/mortality , Skin Neoplasms/therapy
13.
Oncol Rep ; 14(1): 113-20, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15944777

ABSTRACT

Patients with advanced cancer are known to have dysfunctions of the immune system. Dendritic cells (DCs) are potent antigen-presenting cells that play a crucial role in antitumor immune response. At least two peripheral blood DC subsets have been described: myeloid-derived CD11c+CD123- DCs (DC1) and lymphoid-derived CD11c-CD123+ DCs (DC2). Upon interaction with T cells, DC2 seemed to support the generation of a Th2 response, while DC1 predominantly prime a Th1 response. Our study was aimed at investigating the number of circulating DCs, and their subsets and functions in 32 patients with advanced breast cancer that achieved an objective response after a standard-dose sequential chemotherapy (CT), compared to 40 healthy controls. Circulating DC subsets and intracellular cytokine production in CD4+ and CD8+ subsets were analyzed using a tri-color flow cytometry assay. DC subsets were identified in peripheral blood, calculating their percentage gated as lin- HLA-DR+ and using BDCA-1, BDCA-2 and BDCA-3 specific markers, as DC1 and DC2 according to expression of CD11c and CD123, respectively. Intracellular cytokines were evaluated in CD4+(Th1 and Th2) and CD8+ (Tc1 and Tc2) T lymphocytes. The mean percentage of BDCA-1+BDCA-2+BDCA-3 was similar to that of DC1+DC2 (p=ns). The mean percentage of DCs and DC1/DC2 ratio were slightly decreased before CT in cancer patients compared with healthy controls (p=ns). After CT, the percent-age of DC1 further decreased (p=0.02). The production of IFN-gamma (Th1 and Tc1) significantly decreased (p<0.03) while that of IL-4 (Th2 and Tc2) increased (p=0.04), thus confirming a shift toward a Th2 CD4 and Tc2 CD8 phenotype and the predominance of type 2 DCs. Our results could help clarify the mechanisms of the immune response or immune status of patients with advanced breast cancer that undergo cytotoxic CT and contribute to improve the selection of potential candidates for active immunotherapy trials.


Subject(s)
Breast Neoplasms/blood , Cytokines/metabolism , Dendritic Cells/immunology , Flow Cytometry/methods , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , CD11c Antigen/analysis , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/metabolism , Cell Lineage/drug effects , Cell Lineage/immunology , Dendritic Cells/cytology , Dendritic Cells/drug effects , Female , HLA-DR Antigens/analysis , Humans , Interferon-gamma/metabolism , Interleukin-3 Receptor alpha Subunit , Interleukin-4/metabolism , Intracellular Space/drug effects , Intracellular Space/metabolism , Middle Aged , Receptors, Interleukin-3/analysis , Tetradecanoylphorbol Acetate/pharmacology , Time Factors , Treatment Outcome
14.
Arthritis Res Ther ; 7(2): R230-40, 2005.
Article in English | MEDLINE | ID: mdl-15743469

ABSTRACT

We have previously described enrichment of antigen-presenting HLA-DR+ nuclear RelB+ dendritic cells (DCs) in rheumatoid arthritis (RA) synovium. CD123+HLA-DR+ plasmacytoid DCs (pDCs) and their precursors have been identified in human peripheral blood (PB), lymphoid tissue, and some inflamed tissues. We hypothesized recruitment of pDCs into the inflamed RA synovial environment and their contribution as antigen-presenting cells (APCs) and inflammatory cells in RA. CD11c+ myeloid DCs and CD123+ pDCs were compared in normal and RA PB, synovial fluid (SF), and synovial tissue by flow cytometry, immunohistochemistry, and electron microscopy and were sorted for functional studies. Nuclear RelB-CD123+ DCs were located in perivascular regions of RA, in a similar frequency to nuclear RelB+CD123- DCs, but not normal synovial tissue sublining. Apart from higher expression of HLA-DR, the numbers and phenotypes of SF pDCs were similar to those of normal PB pDCs. While the APC function of PB pDCs was less efficient than that of PB myeloid DCs, RA SF pDCs efficiently activated resting allogeneic PB T cells, and high levels of IFN-gamma, IL-10, and tumor necrosis factor alpha were produced in response to incubation of allogeneic T cells with either type of SF DCs. Thus, pDCs are recruited to RA synovial tissue and comprise an APC population distinct from the previously described nuclear RelB+ synovial DCs. pDCs may contribute significantly to the local inflammatory environment.


Subject(s)
Arthritis, Rheumatoid/pathology , Autoimmune Diseases/pathology , Dendritic Cells/pathology , Synovial Membrane/pathology , Antigen Presentation , Arthritis, Psoriatic/pathology , Arthritis, Rheumatoid/immunology , Autoimmune Diseases/immunology , CD11c Antigen/analysis , Cell Count , Cell Differentiation , Cells, Cultured/immunology , Cytokines/analysis , Dendritic Cells/classification , Dendritic Cells/metabolism , Female , Flow Cytometry , Humans , Immunoenzyme Techniques , Interleukin-3 Receptor alpha Subunit , Lymphocyte Activation , Lymphocyte Culture Test, Mixed , Male , Receptors, Interleukin-3/analysis , Spondylitis, Ankylosing/pathology , Synovial Membrane/immunology , T-Lymphocyte Subsets/immunology , Transcription Factor RelB/analysis , Tumor Necrosis Factor-alpha/metabolism
15.
J Pathol ; 205(4): 426-34, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15714455

ABSTRACT

Using immunohistochemistry the presence of different dendritic cell (DC) subsets was analysed in 16 biopsies from patients with oral lichen planus (OLP). A significant increase of CD1a+/Langerin+ Langerhans cells, DC-SIGN+ DC and CD123+/BDCA2+ plasmacytoid DCs (PDCs) was found in the epithelium and in the stroma of OLP biopsies compared to normal oral mucosa. A proportion of DCs were mature DC-LAMP+ and expressed S100 or CD11c, typically found in the interdigitating DCs of nodal T-cell areas. Double staining revealed that mature DCs co-expressed CCR7, thus indicating the development of a nodal migratory phenotype upon maturation. Significant recruitment of PDCs producing IFN-alpha was demonstrated by the expression of MxA within the lichenoid inflammatory infiltrate and close cell-to-cell contacts between PDCs and mature DCs were observed, with a significant correlation between the numbers of these two populations. Moreover, PDCs were also found to contain Granzyme-B, an associated-cytotoxic granule protein, inducing target cell apoptosis. Taken together, these results suggest that PDCs may promote maturation of DCs and amplify the cytotoxicity of lymphoid cells. Finally, the recruitment of different subtypes of DC, such as Langerhans cells, stromal DC-SIGN+ DCs and PDCs, associated with a significant proportion of mature DCs, acquiring a CCR7+ 'migratory' phenotype, indicate that they may play a pivotal role in the development of the lichenoid inflammatory infiltrate that occurs typically in OLP.


Subject(s)
Dendritic Cells/pathology , Lichen Planus, Oral/pathology , Antigens, CD/analysis , Antigens, CD1/analysis , Antigens, Surface/analysis , Cell Adhesion Molecules/analysis , Dendritic Cells/chemistry , Epithelial Cells/chemistry , Epithelial Cells/pathology , Fluorescent Antibody Technique/methods , Humans , Immunohistochemistry/methods , Interleukin-3 Receptor alpha Subunit , Langerhans Cells/chemistry , Langerhans Cells/pathology , Lectins, C-Type/analysis , Lichen Planus, Oral/metabolism , Lysosomal Membrane Proteins , Mannose-Binding Lectins/analysis , Membrane Glycoproteins , Mouth Mucosa/chemistry , Mouth Mucosa/pathology , Nerve Tissue Proteins/analysis , Phenotype , Receptors, CCR7 , Receptors, Cell Surface/analysis , Receptors, Chemokine/analysis , Receptors, Immunologic , Receptors, Interleukin-3/analysis , Stromal Cells/chemistry , Stromal Cells/pathology
16.
Ann Dermatol Venereol ; 131(11): 969-73, 2004 Nov.
Article in French | MEDLINE | ID: mdl-15602384

ABSTRACT

BACKGROUND: Agranular CD4+ CD56+ hematodermic neoplasm (blastic NK-cell lymphoma) has been recently described. The skin is often the first organ involved. OBSERVATIONS: Two old men of respectively 70 and 77 years consulted for infiltrated cutaneous lesions. Preliminary histological examination of cutaneous biopsy taken in both patients showed a malignant proliferation suggesting a cutaneous lymphoma, and the patients were referred. Histological examination of new biopsies showed a very similar proliferation in the 2 cases of monotonous medium-sized mononuclear cells without expression of the common antigens CD3 and CD20 and the expression of CD4, CD56, and CD123. No rearrangement of the T-cell receptor gene or the immunoglobulin heavy chain gene were evidenced. No extracutaneous involvement was initially detected in the first patient. Thrombocytopenia associated with the abnormal presence of 15 p. 100 of circulating CD4+ CD56+ cells was initially found in the second patient. The first patient was treated with chemotherapy, with complete remission. A cutaneous relapse promptly occurred, followed by bone and cerebral localizations. The patient died one year after the diagnosis of the disease, in spite of intensification of the treatment. Treatment is still ongoing in the second patient. COMMENTS: The histological presentation of these two patients was very similar with an unusual phenotype of tumor cells expressing CD4, CD56, CD123, but not expressing CD3 and CD20. Some cases have been published under the "term of blastic NK lymphoma" which is the actual term for the disease in the WHO classification. However, the tumor cells derive from the dendritic plasmacytoid cells, also called type 2 dendritic cells, and perhaps from a common precursor to lymphocyte T and dendritic plasmacytoid cells. In spite of complete cutaneous response in the 2 cases presented, as in other reports, extra-cutaneous involvement occurs quickly. Overall survival is usually poor since nearly all the patients died in less than 3 years. This justifies attempting aggressive protocols, with bone marrow allograft in the younger patients.


Subject(s)
CD4 Antigens/analysis , CD56 Antigen/analysis , Killer Cells, Natural , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/pathology , Receptors, Interleukin-3/analysis , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fatal Outcome , Humans , Interleukin-3 Receptor alpha Subunit , Lymphoma, Non-Hodgkin/drug therapy , Male , Phenotype , Skin Neoplasms/drug therapy
17.
Infect Immun ; 72(12): 7202-11, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15557645

ABSTRACT

Unmethlylated CpG dinucleotides induce a strong T-helper-1-like inflammatory response, presumably mediated by Toll-like receptor 9 (TLR9). However, the nature and cellular localization of TLR9 in primary human cells remain controversial. Here we demonstrate, using flow cytometry and immunofluorescence microscopy techniques, that TLR9 can be expressed at the cell surface. The primary human cell subsets that were positive for TLR9 expression were distinct depending on the tissues analyzed. Specifically, in human peripheral blood mononuclear cells (PBMC) the majority of cell surface TLR9(+) cells were confined to the major histocompatibility complex (MHC) class II(+) CD19(-) populations that express CD11c and/or CD14, whereas in tonsils the same gated population contained primarily MHC class II(+) CD19(+) cells. Cells positive for surface expression represented a minor fraction of the total cell populations examined, varying between 2 and 10%. In addition, we found that TLR9 expression at the surface of PBMC was up-regulated approximately fourfold following stimulation with the gram-negative bacterial cell wall component lipopolysaccharide, suggesting a potential modulatory role of TLR4 agonists on TLR9 expression. Taken together, these data validate human TLR9 expression at the surface of primary cells, in addition to the previously described intracellular localization. Further, our results suggest that human antigen-presenting cells comprise the major cell populations expressing cell surface TLR9.


Subject(s)
DNA-Binding Proteins/analysis , Leukocytes, Mononuclear/chemistry , Palatine Tonsil/chemistry , Receptors, Cell Surface/analysis , Amino Acid Sequence , Antigens, CD19/analysis , CD11c Antigen/analysis , Flow Cytometry , Fluorescent Antibody Technique , Humans , Interleukin-3 Receptor alpha Subunit , Lipopolysaccharides/pharmacology , Molecular Sequence Data , Receptors, Interleukin-3/analysis , Staining and Labeling , Toll-Like Receptor 9
18.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 12(5): 684-6, 2004 Oct.
Article in Chinese | MEDLINE | ID: mdl-15498135

ABSTRACT

The aim of this study was to find new idea for clinical treatment of aplastic anemia. Immune-mediated aplastic anemia mice were developed, IL-3 in the supernatant with PHA stimulating splenic cells was detected by ELISA, semi-quantiting analysis of IL-3R was performed by point hybridization. The results showed that the IL-3 level in the supernatant with PHA stimulating splenic cells of immune-mediated aplastic anemia mice was higher than controls, difference between them was significant (P <0.001), while amount of IL-3 receptor by semi-quantiting analysis was lower than control significantly. In conclusion, the IL-3 receptor expression level is important for pathogenesis and treatment strategy of aplastic anemia.


Subject(s)
Anemia, Aplastic/immunology , Interleukin-3/analysis , Receptors, Interleukin-3/analysis , Anemia, Aplastic/pathology , Animals , Bone Marrow/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred DBA , RNA, Messenger/analysis , Receptors, Interleukin-3/genetics
19.
Ann Pathol ; 24(3): 241-55; quiz 227, 2004 Jun.
Article in French | MEDLINE | ID: mdl-15480259

ABSTRACT

Hematodermic CD4/CD56 neoplasm is a recently described entity. This name has been initially proposed by the French Study Group on Cutaneous Lymphomas which established the primary anatomoclinical and pathogenic and cytogenic bases of the disease in 1999. This descriptive and provisional name allowed conceptualizing the entity by its main clinical and phenotypical characteristics. The first case in the literature goes back to 1994. Since that time, several other cases have been published. The expression of CD56 led most of the authors to propose an NK-cell lineage origin. In the last WHO classification of lymphomas, the entity was indexed under the name of "blastic NK-cell lymphoma". However, the authors underlined that there were currently no clues to the etiology of blastic NK-cell lymphoma and that the precise lineage of this disease was still unresolved. At the clinical level the main characteristics of the disease are the skin tropism and the occurrence of a leukemic phase at any time during the course of the disease. The median age is 59 but pediatric cases do exist. At the morphological level skin biopsy shows a monomorphous cell proliferation simulating a pleomorphic T cell cutaneous lymphoma. The diagnosis is based on phenotypic criteria which require frozen tissue. Currently, the main characteristics are the expression of CD4 and CD56 antigens while the main defined lineage specific markers are negative (B-cell, T-cell, NK-cell and myeloid-cell lineages). The origin of the tumor cells still remains uncertain but the plasmacytoid dendritic cell is presently a very serious candidate. The tumor cells share a great phenotypical homology and particularly the expression of the CD123 antigen. Functional homologies have also been demonstrated with tumor cells in vitro. Outcome of CD4/CD56 hematodermic neoplasms is very bad. The median time of survival is 14 months irrespective of the treatment given. Conventional chemotherapies used for the treatment of aggressive lymphomas or acute myeloid leukemias are quickly inefficient.


Subject(s)
Antigens, Neoplasm/analysis , CD4 Antigens/analysis , CD56 Antigen/analysis , Lymphoma, Non-Hodgkin/pathology , Skin Neoplasms/pathology , Adolescent , Adult , CD4-Positive T-Lymphocytes/pathology , Child , Chromosome Aberrations , Dendritic Cells/classification , Dendritic Cells/pathology , Diagnosis, Differential , Female , Humans , Immunophenotyping , Interleukin-3 Receptor alpha Subunit , Karyotyping , Killer Cells, Natural/pathology , Lymphoma, Non-Hodgkin/chemistry , Lymphoma, Non-Hodgkin/classification , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/genetics , Male , Middle Aged , Neoplastic Stem Cells/pathology , Receptors, Interleukin-3/analysis , Skin Neoplasms/chemistry , Skin Neoplasms/classification , Skin Neoplasms/diagnosis , Skin Neoplasms/genetics
20.
Histopathology ; 45(3): 291-7, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15330808

ABSTRACT

AIM: To study human fetal pancreatic tissue between 15 weeks of gestation and term, analysing the development of pancreatic lymphoid tissue and focusing on the presence and maturational status of dendritic cells (DCs). During normal human fetal pancreatic development lymphoid tissue arises in and around the pancreas. DCs are antigen-presenting cells which are capable of initiating immunity, but are also essential in inducing and maintaining T-cell tolerance. METHODS AND RESULTS: First, the presence and general composition of intra- and peripancreatic lymphoid tissue was investigated by histology and immunohistochemistry with antibodies to CD3, CD4, CD8, CD14, CD20, CD68, and CD79. Intrapancreatic lymphoid tissue (IPLT) appeared to be present only from 29 weeks of gestation onwards, and had a similar composition to peripancreatic lymphoid tissue (PPLT), which was found in all 23 specimens examined. Both forms of lymphoid tissue had an architecture similar to lymph nodes, with separate B- and T-lymphocyte areas and scattered macrophages. DCs were investigated in detail by immunohistochemistry for CD1a, CD83, CD86, CD123, Langerin, and DC-LAMP. Both Langerin, a marker for immature DCs, as well as DC-LAMP, a marker for mature DCs, were expressed by cells in both the IPLT and PPLT at all ages examined. CONCLUSION: The presence of DCs at all developmental stages, expressing various maturation-related markers, in addition to the general composition of the human fetal PPLT and IPLT suggests that this is fully functional and has a function comparable to peripheral lymph nodes.


Subject(s)
Lymphoid Tissue/chemistry , Pancreas/chemistry , Antigens, CD/analysis , Antigens, CD1/analysis , Antigens, CD20/analysis , Antigens, Differentiation, Myelomonocytic/analysis , B7-2 Antigen , CD3 Complex/analysis , CD4 Antigens/analysis , CD79 Antigens , CD8 Antigens/analysis , Dendritic Cells/chemistry , Fetus , Frozen Sections , Gestational Age , Humans , Immunoglobulins/analysis , Immunohistochemistry , Interleukin-3 Receptor alpha Subunit , Lipopolysaccharide Receptors/analysis , Lymphoid Tissue/embryology , Membrane Glycoproteins/analysis , Pancreas/embryology , Paraffin Embedding , Receptors, Antigen, B-Cell/analysis , Receptors, Interleukin-3/analysis , CD83 Antigen
SELECTION OF CITATIONS
SEARCH DETAIL
...